BACKGROUND: Improved outcomes have recently been reported for rituximab (R) plus rituximab plus infusional etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-EPOCH) chemotherapy in patients with human immunodeficiency virus (HIV)-associated, aggressive B-cell, non-Hodgkin lymphoma (NHL). The objective of the current analysis was to assess whether patient selection or other factors contributed to this improvement and to identify patients who are at the greatest risk for lethal toxicity. METHODS: The authors performed a pooled analysis of 2 consecutive trials that included 150 patients with HIV-associated NHL who received either R-CHOP (n = 99; Acquired Immunodeficiency Syndrome [AIDS] Malignancy Consortium Trial 010 [AMC010]) or R-EPOCH (n = 51; AMC034). Age-adjusted International Prognostic Index (aaIPI), CD4 count at lymphoma diagnosis (<100/μL vs ≥100/μL), and treatment (R-CHOP vs R-EPOCH) were included as variables in a multivariate logistic regression model for complete response (CR) and in a Cox proportional hazards regression models for event-free survival (EFS) and overall survival (OS). RESULTS: Features that were associated significantly with an improved CR rate and improved EFS and OS included a low aaIPI score and a baseline CD4 count ≥100/μL. When the analysis was adjusted for aaIPI and CD4 count, patients who received concurrent R-EPOCH had improved EFS (hazard ratio [HR] 0.40; 95% confidence intervals [CI], 0.23, 0.69; P < .001) and OS (HR, 0.38; 95% CI, 0.21, 0.69; P < .01). Treatment-associated death occurred significantly more often in patients with CD4 counts <50/μL (37% vs 6%; P < .01). CONCLUSIONS: The current analysis provided additional level 2 evidence supporting the use of concurrent R-EPOCH in patients with HIV-associated lymphoma and a CD4 count >50/μL, and the results support the design of an ongoing phase 3 trial comparing concurrent R-EPOCH with R-CHOP in immunocompetent patients with diffuse large B-cell lymphoma (National Clinical Trial no. NCT00118209).
BACKGROUND: Improved outcomes have recently been reported for rituximab (R) plus rituximab plus infusional etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-EPOCH) chemotherapy in patients with human immunodeficiency virus (HIV)-associated, aggressive B-cell, non-Hodgkin lymphoma (NHL). The objective of the current analysis was to assess whether patient selection or other factors contributed to this improvement and to identify patients who are at the greatest risk for lethal toxicity. METHODS: The authors performed a pooled analysis of 2 consecutive trials that included 150 patients with HIV-associated NHL who received either R-CHOP (n = 99; Acquired Immunodeficiency Syndrome [AIDS] Malignancy Consortium Trial 010 [AMC010]) or R-EPOCH (n = 51; AMC034). Age-adjusted International Prognostic Index (aaIPI), CD4 count at lymphoma diagnosis (<100/μL vs ≥100/μL), and treatment (R-CHOP vs R-EPOCH) were included as variables in a multivariate logistic regression model for complete response (CR) and in a Cox proportional hazards regression models for event-free survival (EFS) and overall survival (OS). RESULTS: Features that were associated significantly with an improved CR rate and improved EFS and OS included a low aaIPI score and a baseline CD4 count ≥100/μL. When the analysis was adjusted for aaIPI and CD4 count, patients who received concurrent R-EPOCH had improved EFS (hazard ratio [HR] 0.40; 95% confidence intervals [CI], 0.23, 0.69; P < .001) and OS (HR, 0.38; 95% CI, 0.21, 0.69; P < .01). Treatment-associated death occurred significantly more often in patients with CD4 counts <50/μL (37% vs 6%; P < .01). CONCLUSIONS: The current analysis provided additional level 2 evidence supporting the use of concurrent R-EPOCH in patients with HIV-associated lymphoma and a CD4 count >50/μL, and the results support the design of an ongoing phase 3 trial comparing concurrent R-EPOCH with R-CHOP in immunocompetent patients with diffuse large B-cell lymphoma (National Clinical Trial no. NCT00118209).
Authors: Chun Chao; Lanfang Xu; Donald Abrams; Wendy Leyden; Michael Horberg; William Towner; Daniel Klein; Beth Tang; Michael Silverberg Journal: AIDS Date: 2010-07-17 Impact factor: 4.177
Authors: François Boué; Jean Gabarre; Christian Gisselbrecht; Jacques Reynes; Antoine Cheret; Fabrice Bonnet; Eric Billaud; Martine Raphael; Remi Lancar; Dominique Costagliola Journal: J Clin Oncol Date: 2006-08-08 Impact factor: 44.544
Authors: P Feugier; A Van Hoof; C Sebban; P Solal-Celigny; R Bouabdallah; C Fermé; B Christian; E Lepage; H Tilly; F Morschhauser; P Gaulard; G Salles; A Bosly; C Gisselbrecht; F Reyes; B Coiffier Journal: J Clin Oncol Date: 2005-05-02 Impact factor: 44.544
Authors: Joseph A Sparano; Jeannette Y Lee; Lawrence D Kaplan; Alexandra M Levine; Juan Carlos Ramos; Richard F Ambinder; William Wachsman; David Aboulafia; Ariela Noy; David H Henry; Jamie Von Roenn; Bruce J Dezube; Scot C Remick; Manisha H Shah; Lawrence Leichman; Lee Ratner; Ethel Cesarman; Amy Chadburn; Ronald Mitsuyasu Journal: Blood Date: 2009-12-18 Impact factor: 22.113
Authors: Joseph A Sparano; Edie Weller; Tipu Nazeer; Thomas Habermann; Ann E Traynor; Jane Manalo; Peter Cassileth Journal: Blood Date: 2002-09-01 Impact factor: 22.113
Authors: Josep-Maria Ribera; Albert Oriol; Mireia Morgades; Eva González-Barca; Pilar Miralles; Armando López-Guillermo; Santiago Gardella; Andres López; Eugenia Abella; Marta García Journal: Br J Haematol Date: 2007-12-19 Impact factor: 6.998
Authors: Erin G Reid; David Looney; Frank Maldarelli; Ariela Noy; David Henry; David Aboulafia; Juan Carlos Ramos; Joseph Sparano; Richard F Ambinder; Jeannette Lee; Ethel Cesarman; Sara Yahyaei; Ronald Mitsuyasu; William Wachsman Journal: Blood Adv Date: 2018-12-26
Authors: Marta Epeldegui; Jeannette Y Lee; Anna C Martínez; Daniel P Widney; Larry I Magpantay; Deborah Regidor; Ronald Mitsuyasu; Joseph A Sparano; Richard F Ambinder; Otoniel Martínez-Maza Journal: Clin Cancer Res Date: 2015-09-17 Impact factor: 12.531
Authors: Elizabeth L Yanik; Chad J Achenbach; Satish Gopal; Anna E Coghill; Stephen R Cole; Joseph J Eron; Richard D Moore; W Christopher Mathews; Daniel R Drozd; Ayad Hamdan; Mary E Ballestas; Eric A Engels Journal: J Clin Oncol Date: 2016-08-09 Impact factor: 44.544
Authors: Yvette L Kasamon; Robert A Brodsky; Michael J Borowitz; Richard F Ambinder; Pamela A Crilley; Steve Y Cho; Hua-ling Tsai; B Douglas Smith; Douglas E Gladstone; Hetty E Carraway; Carol Ann Huff; William H Matsui; Javier Bolaños-Meade; Richard J Jones; Lode J Swinnen Journal: Leuk Lymphoma Date: 2012-08-17
Authors: Satish Gopal; Monita R Patel; Elizabeth L Yanik; Stephen R Cole; Chad J Achenbach; Sonia Napravnik; Greer A Burkholder; Erin G Reid; Benigno Rodriguez; Steven G Deeks; Kenneth H Mayer; Richard D Moore; Mari M Kitahata; Kristy L Richards; Joseph J Eron Journal: AIDS Date: 2013-09-24 Impact factor: 4.177